Targeting mitochondrial oxidative stress through Lipoic acid synthase: A novel strategy to manage diabetic cardiovascular disease

Cardiovascular and Hematological Agents in Medicinal Chemistry

Volumn 10, Issue 3, 2012, Pages 223-233

  Padmalayam, Indira ^a  

^a SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

Antioxidant; Atherosclerosis; Cardiovascular disease; Catalase; Diabetes; Electron transport chain; Free radicals; Glutathione; Inflammation; Insulin resistance; Lipoic acid; Mitochondrial function; Oxidative stress; Pyruvate dehydrogenase; ROS; Superoxide dismutase

Indexed keywords

ANTIOXIDANT; LIPOIC ACID SYNTHASE; REACTIVE OXYGEN METABOLITE; SYNTHETASE; THIOCTIC ACID; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; CARDIOVASCULAR DISEASE; CELL FUNCTION; DISEASE COURSE; ENDOTHELIUM CELL; GREAT BLOOD VESSEL; HEART MUSCLE ISCHEMIA; HUMAN; INFLAMMATION; INSULIN RESISTANCE; KIDNEY; METABOLIC REGULATION; MITOCHONDRION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; REPERFUSION INJURY; REVIEW; SKELETAL MUSCLE; VASCULAR ENDOTHELIUM;

EID: 84864573131     PISSN: 18715257     EISSN: 18756182     Source Type: Journal    
DOI: 10.2174/187152512802651060     Document Type: Review

References (80)

1. Fowler, M.J. Microvascular and Macrovascular Complications of Diabetes. Clin. Diabetes, 2008, 26(2), 77-82.
2. Brownlee, M. Biochemistry and molecular cell biology of diabetic complications. Nature, 2001, 414(6865), 813-820.
3. Nishikawa, T.; Edelstein, D.; Du, X.L.; Yamagishi, S.; Matsumura, T.; Kaneda, Y.; Yorek, M.A.; Beebe, D.; Oates, P.J.; Hammes, H.P.; Giardino, I.; Brownlee, M. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature, 2000, 404(6779),787-790.
4. Giacco F.; Brownlee, M. Oxidative stress and diabetic complications. Circ. Res., 2010, 107(9), 1058-1070.
5. Hayat, S.A.; Patel, B.; Khattar, R.S.; Malik, R.A. Diabetic cardiomyopathy: mechanisms, diagnosis and treatment. Clin. Sci. (Lond), 2004, 107(6), 539-557.
6. Opara, E.C.; Abdel-Rahman, E.; Soliman, S.; Kamel, W.A.; Souka, S.; Lowe, J.E.; Abdel-Aleem, S. Depletion of total antioxidant capacity in type 2 diabetes. Metabolism, 1999, 48(11), 1414-1417.
7. Rahbani-Nobar, M.E.; Rahimi-Pour, A.; Rahbani-Nobar, M.; Adi-Beig, F. Total antioxidant capacity, Superoxide Dismutase and Glutathione Peroxidase in diabetic patients. Med. J. Isl. Acad. Sci., 1999, 12(4), 109-114.
8. Van Campenhout, C.; Lagrou, A.R.; Moorkens, G.; De Block, C.; Manuel-y-Keenoy, B. Iron-binding antioxidant capacity is impaired in diabetes mellitus. Free Radic. Biol. Med., 2006, 40(10), 1749-1755.
9. Lapolla, A.; Piarulli, F.; Sartore, G.; Ceriello, A.; Ragazzi, E.; Reitano, R.; Baccarin, L.; Laverda, B.; Fedele, D. Advanced glycation end products and antioxidant status in type 2 diabetic patients with and without peripheral artery disease. Diabetes Care, 2007, 30(3), 670-676.
10. Guldiken, B.; Demir, M.; Guldiken, S.; Turgut, N.; Turgut, B.; Tugrul, A. Oxidative stress and total antioxidant capacity in diabetic and nondiabetic acute ischemic stroke patients. Clin. Appl. Thromb. Hemost., 2009, 15(6), 695-700.
11. Maritim, A.C.; Sanders, R.A.; Watkins, J.B. 3rd. Diabetes, oxidative stress, and antioxidants: a review. J. Biochem. Mol. Toxicol., 2003, 17(1), 24-38.
12. Pashkow, F.J. Oxidative Stress and Inflammation in Heart Disease. Int. J. Inflam., 2011, 514623.
13. Jacob, S.; Streeper, R.S.; Fogt, D.L.; Hokama, J.Y.; Tritschler, H.J.; Dietze, G.J.; Henriksen, E.J. The antioxidant alpha-lipoic acid enhances insulin-stimulated glucose metabolism in insulin-resistant rat skeletal muscle. Diabetes, 1996, 45(8), 1024-1029.
14. Packer, L.; Tritschler, H.J.; Wessel, K. Neuroprotection by the metabolic antioxidant alpha-lipoic acid. Free Radic. Biol. Med., 1997, 22(1-2), 359-378.
15. Reljanovic, M.G.; Reichel, K.; Rett, M.; Lobisch, K.; Schuette, W.; Moller, H.J.; Tritschler, H.J.; Mehnert, H. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebocontrolled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy. Free Radic. Res., 1999, 31(3), 171-179.
16. Ruhnau, K.J.; Meissner, H.P.; Finn, J.R.; Reljanovic, M.; Lobisch, M.; Schutte, K.; Nehrdich, D.; Tritschler, H.J.; Mehnert, H.; Ziegler, D. Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy. Diabet. Med., 1999, 6(12), 1040-1043.
17. Sachse, G.; Willms, B. Efficacy of thioctic acid in the therapy of peripheral diabetic neuropathy. Horm. Metab. Res. Suppl., 1980, 9, 105-107.
18. Strokov, I.A.; Kozlova, N.A.; Mozolevskii L, V.; Miasoedov, S.P.; Lakhno N.N. The efficacy of the intravenous administration of the trometamol salt of thioctic (alpha-lipoic) acid in diabetic neuropathy. Zh. Nevrol. Psikhiatr. Im. S. S. Korsakova., 1999, 99(6), 18-22.
19. Ziegler, D.; Gries, F.A. Alpha-lipoic acid in the treatment of diabetic peripheral and cardiac autonomic neuropathy. Diabetes, 1997, 46(2), S62-S66.
20. Ziegler, D.; Hanefeld, M.; Ruhnau, K.J.; Meissner, H.P.; Lobisch, M.; Schutte, K.; Gries, F.A. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia, 1995, 38(12), 1425-1433.
21. Ziegler, D.; Schatz, H.; Conrad, F.; Gries, F.A.; Ulrich, H.; Reichel, G. Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). Deutsche Kardiale Autonome Neuropathie. Diabetes Care, 1997, 20(3), 369-373.
22. Shigenaga, M.K.; Hagen, T.M.; Ames, B.N. Oxidative damage and mitochondrial decay in aging. Proc. Natl. Acad. Sci. USA, 1994, 91(23), 10771-10778.
23. Leto, T.L.; Geiszt, M. Role of Nox family NADPH oxidases in host defense. Antioxid. Redox Signal, 2006, 8(9-10), 1549-1561.
24. Shulman, G.I. Cellular mechanisms of insulin resistance. J. Clin. Invest., 2000, 106(2), 171-176.
25. Perseghin, G.; Petersen, K.; Shulman, G.I. Cellular mechanism of insulin resistance: potential links with inflammation. Int. J. Obes. Relat. Metab. Disord., 2003, 27(3), S6-11.
26. Henriksen, E.J.; Diamond-Stanic, M.K.; Marchionne, E.M. Oxidative Stress and the etiology of insulin resistance and type 2 diabetes. Free Radic. Biol. Med., 2011, 51(5), 993-999.
27. Kaneto, H.; Katakami, N.; Matsuhisa, M.; Matsuoka, T.-A. Role of Reactive Oxygen Species in the Progression of Type 2 diabetes and Atherosclerosis. Mediators Inflamm., 2010, 2010, 453892.
28. Meigs, J.B.; Larson, M.G.; Fox, C.S.; Keaney, J.F. Jr.; Vasan, R.S.; Benjamin, E.J. Association of oxidative stress, insulin resistance, and diabetes risk phenotypes: the framingham offspring study. Diabetes Care, 2007, 30(10), 2529-2535.
29. Ceriello, A.; Motz, E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler. Thromb. Vasc. Biol., 2004, 24(5), 816-823.
30. Park, K.; Gross, M.; Lee, D.H.; Holvoet, P.; Himes, J.H.; Shikany, J.M.; Jacobs, D.R. Jr. Oxidative stress and insulin resistance: the coronary artery risk development in young adults study. Diabetes Care, 2009, 32(7), 1302-1307.
31. Ginsberg, H.N. Insulin resistance and cardiovascular disease. J. Clin. Invest., 2000, 106(4), 453-458.
32. De Vriese, A.S.; Verbeuren, T.J.; Van de Voorde, J.; Lameire, N.H.; Vanhoutte, P.M. Endothelial dysfunction in diabetes. Br. J. Pharmacol., 2000, 130(5), 963-974.
33. Freedman, J.E. Oxidative stress and platelets. Arterioscler. Thromb. Vasc. Biol., 2008, 28(3), 11-16.
34. García-Ruiz, C.; Colell, A.; Morales, A.; Kaplowitz, N.; Fernández-Checa, J.C. Role of oxidative stress generated from the mitochondrial electron transport chain and mitochondrial glutathione status in loss of mitochondrial function and activation of transcription factor nuclear factor-kappa B: studies with isolated mitochondria and rat hepatocytes. Mol. Pharmacol., 1995, 48(5), 825-834.
35. Münzel, T.; Gori, T.; Bruno, R.M.; Taddei, S. Is oxidative stress a therapeutic target in cardiovascular disease? Eur. Heart. J., 2010, 31(22), 2741-2748.
36. Johansen, J.S.; Harris, A.K.; Rychly, D.J.; Ergul, A. Oxidative stress and the use of antioxidants in diabetes: linking basic science to clinical practice. Cardiovasc. Diabetol., 2005, 4(1), 5.
37. Brands, M.W.; Bell, T.D.; Gibson, B. Nitric oxide may prevent hypertension early in diabetes by counteracting renal actions of superoxide. Hypertension, 2004, 43(1), 57-63.
38. Smith, A.R.; Shenvi, S.V.; Widlansky, M.; Suh, J.H.; Hagen, T.M. Lipoic acid as a potential therapy for chronic diseases associated with oxidative stress. Curr. Med. Chem., 2004, 11(9), 1135-1146.
39. Packer, L.; Witt, E.H.; Tritschler, H.J. Alpha-Lipoic acid as a biological antioxidant. Free Radic. Biol. Med., 1995, 19(2), 227-250.
40. Rösen, P.; Nawroth, P.P.; King, G.; Möller, W; Tritschler, H.J.; Packer, L. The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab. Res. Rev., 2001, 17(3), 189-212.
41. Ghibu, S.; Richard, C.; Vergely, C.; Zeller, M.; Cottin, Y.; Rochette, L. Antioxidant properties of an endogenous thiol: Alphalipoic acid, useful in the prevention of cardiovascular diseases. J. Cardiovasc. Pharmacol., 2009, 54(5), 391-398.
42. Miranda-Massari, J.R.; Gonzalez, M.J.; Jimenez, F.J.; Allende-Vigo, M.Z.; Duconge, J. Metabolic Correction in the Management of Diabetic Peripheral Neuropathy: Improving Clinical Results Beyond Symptom Control. Curr. Clin. Pharmacol. 2011, 6(4), 260-273.
43. Konrad, T.; Vicini, P.; Kusterer, K.; Höflich, A.; Assadkhani, A.; Böhles, H.J.; Sewell, A.; Tritschler, H.J.; Cobelli, C.; Usadel, K.H. Alpha-Lipoic acid treatment decreases serum lactate and pyruvate concentrations and improves glucose effectiveness in lean and obese patients with type 2 diabetes. Diabetes Care, 1999, 22(2), 280-287.
44. Jacob, S.; Ruus, P.; Hermann, R.; Tritschler, H.J.; Maerker, E.; Renn, W.; Augustin, H.J.; Dietze, G.J.; Rett, K. Oral administration of RAC-alpha-lipoic acid modulates insulin sensitivity in patients with type-2 diabetes mellitus: a placebo-controlled pilot trial. Free Radic. Biol. Med., 1999, 27(3-4), 309-314.
45. Kandeil, M.A.; Amin, K.A.; Hassanin, K.A.; Ali, K.M.; Mohammed, E.T. Role of lipoic acid on insulin resistance and leptin in experimentally diabetic rats. J. Diabetes Complications, 2011, 25(1), 31-38.
46. Estrada, D.E.; Ewart, H.S.; Tsakiridis, T.; Volchuk, A.; Ramlal, T.; Tritschler, H.; Klip, A. Stimulation of glucose uptake by the natural coenzyme alpha-lipoic acid/thioctic acid: participation of elements of the insulin signaling pathway. Diabetes, 1996, 45(12), 1798-1804.
47. Maddux, B.A.; See, W.; Lawrence, J.C. Jr.; Goldfine, A.L.; Goldfine, I.D.; Evans, J.L. Stimulation of glucose uptake by the natural coenzyme alpha-lipoic acid/thioctic acid: participation of elements of the insulin signaling pathway. Diabetes, 2001, 50(2), 404-410.
48. Vincent, A.M.; Callaghan, B.C.; Smith, A.L.; Feldman, E.L. Diabetic neuropathy: cellular mechanisms as therapeutic targets. Nat. Rev. Neurol., 2011, 7(10), 573-583.
49. Ziegler, D. Painful diabetic neuropathy: advantage of novel drugs over old drugs? Diabetes Care, 2009, 32(2), 414-419.
50. Yamada, T.; Hashida, K.; Takarada-Iemata, M.; Matsugo, S.; Hori, O. Lipoic acid (LA) enantiomers protect SH-SY5Y cells against glutathione depletion. Neurochem. Int., 2011, 59(7), 1003-1009.
51. McIlduff, C.E.; Rutkove, S.B. Critical appraisal of the use of alpha lipoic acid (thioctic acid) in the treatment of symptomatic diabetic polyneuropathy. Ther. Clin. Risk Manag., 2011, 7, 377-385.
52. Shakher, J.; Stevens, M.J. Update on the management of diabetic polyneuropathies. Diabetes Metab. Syndr. Obes., 2011, 4, 289-305.
53. Ziegler, D.; Nowak, H.;, Kempler, P.; Vargha, P.; Low, P.A. Treatment of symptomatic diabetic poly neuropathy with alphalipoic acid: a meta-analysis. Diabetic Med., 2004, 21(4), 114-121.
54. Tesfaye, S.; Vileikyte, L.; Rayman, G.; Sindrup, S.; Perkins, B.;, Baconja, M.; Vinik, A.; Boulton, A.; on behalf of the Toronto expert panel on diabetic neuropathy. Painful Diabetic Peripheral Neuropathy: Consensus Recommendations on Diagnosis, Assessment and Management. Diabetes Metab. Res. Rev., 2011, Jun 21. doi: 10.1002/dmrr.1225. [Epub ahead of print]
55. Skalská, S.; Kucera, P.; Goldenberg, Z.; Stefek, M.; Kyselová, Z.; Jariabka, P.; Gajdosíková, A.; Klobucníková, K.; Traubner, P.; Stolc, S. Neuropathy in a rat model of mild diabetes induced by multiple low doses of streptozotocin: effects of the antioxidant stobadine in comparison with a high-dose alpha-lipoic acid treatment. Gen. Physiol. Biophys., 2010, 29(1), 50-58.
56. Vallianou, N.; Evangelopoulos, A.; Koutalas, P. Alpha-lipoic Acid and diabetic neuropathy. Rev. Diabet. Stud., 2009, 6(4), 230-236.
57. Visioli, F.; Smith, A.; Zhang, W.; Keaney, J.F. Jr.; Hagen, T.;Frei, B. Lipoic acid and vitamin C potentiate nitric oxide synthesis in human aortic endothelial cells independently of cellular glutathione status. Redox Rep., 2002, 7(4), 223-227.
58. Heitzer, T.; Finckh, B.; Albers, S.; Krohn, K.; Kohlschütter, A.; Meinertz, T. Beneficial effects of alpha-lipoic acid and ascorbic acid on endothelium-dependent, nitric oxide-mediated vasodilation in diabetic patients: relation to parameters of oxidative stress. Free Radic. Biol. Med., 2001, 31(1), 53-61.
59. Heinisch, B.B.; Francesconi, M.; Mittermayer, F.; Schaller, G.; Gouya, G.; Wolzt, M.; Pleiner, J. Alpha-lipoic acid improves vascular endothelial function in patients with type 2 diabetes: a placebo-controlled randomized trial. Eur. J. Clin. Invest., 2010, 40(2), 148-154.
60. Rahman, S.T.; Merchant, N.; Haque, T.; Wahi, J.; Bhaheetharan, S.; Ferdinand, K.C.; Khan, B.V. The impact of lipoic acid on endothelial function and proteinuria in Quinapril-treated diabetic patients with stage I hypertension: results from the quality study. J. Cardiovasc. Pharmacol. Ther., 2011 Jul 12. [Epub ahead of print]
61. Gorca, A.; Huk-Kolega, H.; Piechota, A.; Kleniewska, P.; Ciejka, E.; Skibska, B. Lipoic acid-biological activity and therapeutic potential. Pharmacol. Rep., 2011, 63(4), 849-858.
62. Zhang, Y.; Han, P.; Wu, N.; He, B.; Lu, Y.; Li, S.; Liu, Y.; Zhao, S.; Liu, L.; Li, Y. Amelioration of lipid abnormalities by _-lipoic acid through antioxidative and anti-inflammatory effects. Obesity (Silver Spring), 2011, 19(8), 1647-1653.
63. Khabbazi, T.; Mahdavi, R.; Safa, J.; Pour-Abdollahi, P. Effects of alpha-lipoic acid supplementation on inflammation, oxidative stress, and serum lipid profile levels in patients with end-stage renal disease on hemodialysis. J. Ren. Nutr. 2011, 22(2), 244-250.
64. Wang, X.; Yu, Y.; Ji, L.; Liang, X.; Zhang, T.; Hai, C.X. Alphalipoic acid protects against myocardial ischemia/reperfusion injury via multiple target effects. Food Chem. Toxicol., 2011, 49(11), 2750-2757.
65. Vasdev, S.; Gill, V.D.; Parai, S.; Gadag, V. Effect of moderately high dietary salt and lipoic acid on blood pressure in Wistar-Kyoto rats. Exp. Clin. Cardiol. 2007, 12(2), 77-81.
66. El Midaoui, A.; de Champlain, J. Prevention of hypertension, insulin resistance, and oxidative stress by alpha-lipoic acid. Hypertension, 2002, 39(2), 303-307.
67. Brown, S.E.; Ross, M.F.; Sanjuan-Pla, A.; Manas, A.R.; Smith, R.A.; Murphy, M.P. Targeting lipoic acid to mitochondria: synthesis and characterization of a triphenylphosphoniumconjugated alpha-lipoyl derivative. Free Radic. Biol. Med., 2007, 42(12), 1766-1780.
68. Ripcke, J.; Zarse, K.; Ristow, M.; Birringer, M. Small-molecule targeting of the mitochondrial compartment with an endogenously cleaved reversible tag. Chembiochem., 2009, 10(10), 1689-1696.
69. Morikawa, T.; Yasuno, R.; Wada, H. Do mammalian cells synthesize lipoic acid? Identification of a mouse cDNA encoding a lipoic acid synthase located in mitochondria. FEBS Lett., 2001, 498(1), 16-21.
70. Yi, X.; Maeda, N. Endogenous production of lipoic acid is essential for mouse development. Mol. Cell Biol., 2005, 25(18), 8387-8392.
71. Navarro-Sastre, A.; Tort, F.; Stehling, O.; Uzarska, M.A.; Arranz, J.A.; Del Toro, M.; Labayru, M.T.; Landa, J.; Font, A.; Garcia-Villoria, J.; Merinero, B.; Ugarte, M.; Gutierrez-Solana, L.G.; Campistol, J.; Garcia-Cazorla, A.; Vaquerizo, J.; Riudor, E.; Briones, P.; Elpeleg, O.; Ribes, A.; Lill, R. A Fatal Mitochondrial Disease Is Associated with Defective NFU1 Function in the Maturation of a Subset of Mitochondrial Fe-S Proteins. Am. J. Hum. Genet., 2011, 89(5), 656-667.
72. Mayr, J.A.; Zimmermann, F.A.; Fauth, C.; Bergheim, C.; Meierhofer, D.; Radmayr, D.; Zschocke, J.; Koch, J.; Sperl, W. Lipoic acid synthetase deficiency causes neonatal-onset epilepsy, defective mitochondrial energy metabolism, and glycine elevation. Am. J. Hum. Genet., 2011, 89(6), 792-797.
73. Hiltunen, J.K.; Autio, K.J. Schonauer, M.S.; Kursu, V.A.; Dieckmann, C.L.; Kastaniotis, A.J. Mitochondrial fatty acid synthesis and respiration. Biochim. Biophys. Acta, 2010, 1797(6-7), 1195-1202.
74. Padmalayam, I.; Hasham, S.; Saxena, U.; Pillarisetti, S. Lipoic Acid Synthase (LASY): A Novel Role in Inflammation, Mitochondrial Function and Insulin Resistance. Diabetes, 2009, 58(3), 600-608.
75. Yi, X.; Nickeleit, V.; James, L.R.; Maeda, N. Lipoic acid protects diabetic apolipoprotein E-deficient mice from nephropathy. J. Diabetes Complications, 2011, 25(3), 193-201.
76. Yi, X.; Xu, L.; Kim, K.; Kim, H.S.; Maeda, N. Genetic reduction of lipoic acid synthase expression modestly increases atherosclerosis in male, but not in female, apolipoprotein E-deficient mice. Atherosclerosis, 2010, 211(2), 424-430.
77. Yi, X.; Xu, L.; Hiller, S.; Kim, H.S.; Nickeleit, V.; James, L.R.; Maeda, N. Reduced Expression of Lipoic Acid Synthase Accelerates Diabetic Nephropathy. J. Am. Soc. Nephrol., 2011, 23(1), 103-111.
78. Liu, C.; Lv, X.H.; Li, H.X.; Cao, X.; Zhang, F.; Wang, L.; Yu, M.; Yang, J.K. Angiotensin-(1-7) suppresses oxidative stress and improves glucose uptake via Mas receptor in adipocytes. Acta Diabetol., 2011, Nov 1. [Epub ahead of print].
79. Wang, Z.; Dou, X.; Gu, D.; Shen, C.; Yao, T.; Nguyen, V.; Braunschweig, C.; Song, Z. 4-Hydroxynonenal differentially regulates adiponectin gene expression and secretion via activating PPAR_ and accelerating ubiquitin-proteasome degradation. Mol. Cell Endocrinol., 2011, 349(2), 222-231.
80. Uribarri, J.; Cai, W.; Ramdas, M.; Goodman, S.; Pyzik, R.; Chen, X.; Zhu, L.; Striker, G.E.; Vlassara, H. Restriction of advanced glycation end products improves insulin resistance in human type 2 diabetes: potential role of AGER1 and SIRT1. Diabetes Care, 2011, 34(7), 1610-1616.